502,817 Shares in Boston Scientific Corporation $BSX Acquired by Nykredit A S

Key Points

• Nykredit A/S acquired 502,817 Boston Scientific shares during the second quarter, worth approximately $21.46 million. Institutional investors collectively own 89.07% of the company.
• Analysts maintain a generally positive outlook, with 23 Buy, six Hold, and two Sell ratings; the stock has an average “Moderate Buy” rating and a consensus price target of $71.04.
• Boston Scientific exceeded quarterly expectations, reporting $0.86 earnings per share and $5.44 billion in revenue, up 7.5% year over year. Two directors also purchased shares recently, contributing to $9.39 million in insider buying over the past 90 days.

Nykredit A S bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 502,817 shares of the medical equipment provider's stock, valued at approximately $21,460,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Kelleher Financial Advisors purchased a new position in Boston Scientific in the second quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Boston Scientific during the 1st quarter worth about $28,000. Rakuten Securities Inc. purchased a new stake in Boston Scientific during the 2nd quarter worth about $30,000. Cassaday & Co Wealth Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at about $32,000. Finally, Cetera Trust Company N.A acquired a new stake in Boston Scientific in the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. Piper Sandler restated an "overweight" rating and set a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. Barclays dropped their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an "overweight" rating on the stock in a research report on Thursday, May 28th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, UBS Group decreased their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Twenty-three analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $71.04.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger bought 2,100 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig purchased 5,000 shares of the company's stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Insiders own 0.34% of the company's stock.

Boston Scientific Price Performance

BSX stock opened at $43.41 on Friday. The business has a 50 day moving average price of $46.90 and a 200 day moving average price of $53.57. The stock has a market cap of $62.91 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.01 and a beta of 0.57. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the firm posted $0.75 earnings per share. The firm's revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.28 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.